BVF Inc’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,560,916
| Closed | -$170M | – | 47 |
|
|
2025
Q3 | $170M | Sell |
2,560,916
-650,125
| -20% | -$37M | 6.9% | 3 |
|
|
2025
Q2 | $177M | Buy |
3,211,041
+636,026
| +25% | +$30.5M | 6.34% | 4 |
|
|
2025
Q1 | $125M | Buy |
2,575,015
+675,000
| +36% | +$28.3M | 5.08% | 6 |
|
|
2024
Q4 | $73.3M | Buy |
1,900,015
+49,848
| +3% | +$2.17M | 2.49% | 7 |
|
|
2024
Q3 | $83.3M | Sell |
1,850,167
-1,469,123
| -44% | -$59.4M | 2.44% | 11 |
|
|
2024
Q2 | $115M | Sell |
3,319,290
-436,700
| -12% | -$12.8M | 3.22% | 7 |
|
|
2024
Q1 | $109M | Sell |
3,755,990
-1,988,858
| -35% | -$54.1M | 2.99% | 8 |
|
|
2023
Q4 | $132M | Hold |
5,744,848
| – | – | 3.3% | 4 |
|
|
2023
Q3 | $95.8M | Buy |
5,744,848
+1,968,948
| +52% | +$38.2M | 2.58% | 9 |
|
|
2023
Q2 | $104M | Hold |
3,775,900
| – | – | 2.91% | 8 |
|
|
2023
Q1 | $86.8M | Buy |
+3,775,900
| New | +$63.4M | 3.17% | 6 |
|
|
2022
Q3 | – | Sell |
-1,106,838
| Closed | -$8.76M | – | 82 |
|
|
2022
Q2 | $8.76M | Sell |
1,106,838
-3,076,381
| -74% | -$37.2M | 0.42% | 53 |
|
|
2022
Q1 | $99.1M | Buy |
4,183,219
+531,460
| +15% | +$15M | 3.96% | 7 |
|
|
2021
Q4 | $125M | Sell |
3,651,759
-250,000
| -6% | -$7.9M | 4.53% | 5 |
|
|
2021
Q3 | $69.1M | Buy |
3,901,759
+147,664
| +4% | +$6.3M | 2.7% | 9 |
|
|
2021
Q2 | $168M | Sell |
3,754,095
-205,356
| -5% | -$6.78M | 6.31% | 4 |
|
|
2021
Q1 | $103M | Sell |
3,959,451
-314,137
| -7% | -$7.95M | 3.84% | 7 |
|
|
2020
Q4 | $86.2M | Buy |
4,273,588
+1,901,300
| +80% | +$40.9M | 3.39% | 9 |
|
|
2020
Q3 | $46.4M | Buy |
2,372,288
+5,000
| +0.2% | +$93.8K | 2.53% | 11 |
|
|
2020
Q2 | $41.8M | Buy |
2,367,288
+1,674,858
| +242% | +$21M | 2.58% | 16 |
|
|
2020
Q1 | $4.89M | Buy |
692,430
+9,800
| +1% | +$73.4K | 0.46% | 39 |
|
|
2019
Q4 | $4.81M | Hold |
682,630
| – | – | 0.36% | 40 |
|
|
2019
Q3 | $8.2M | Sell |
682,630
-381,172
| -36% | -$4.8M | 0.86% | 33 |
|
|
2019
Q2 | $12.9M | Sell |
1,063,802
-59,453
| -5% | -$657K | 1.41% | 24 |
|
|
2019
Q1 | $14.1M | Sell |
1,123,255
-516,203
| -31% | -$4.56M | 1.58% | 22 |
|
|
2018
Q4 | $11M | Sell |
1,639,458
-978,509
| -37% | -$7.76M | 1.44% | 25 |
|
|
2018
Q3 | $26.9M | Buy |
2,617,967
+1,200,000
| +85% | +$10.3M | 2.37% | 14 |
|
|
2018
Q2 | $9.53M | Buy |
1,417,967
+1,012,367
| +250% | +$7.77M | 0.93% | 29 |
|
|
2018
Q1 | $3.48M | Buy |
405,600
+111,483
| +38% | +$2.1M | 0.35% | 39 |
|
|
2017
Q4 | $6.12M | Buy |
+294,117
| New | +$5.22M | 0.74% | 31 |
|
|
2016
Q4 | – | Sell |
-375,000
| Closed | -$7.92M | – | 31 |
|
|
2016
Q3 | $7.92M | Buy |
+375,000
| New | +$5.13M | 1.49% | 20 |
|
Other funds holding PTGX
FCM
RI
JJ
BVF Inc's PTGX Position: Q4 2025 in Review
BVF Inc sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 2,560,916 shares — an estimated $170M sold.
BVF Inc first reported a position in PTGX in Q3 2016 and held it in 31 quarters. The position peaked at $177M in Q2 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.
- BVF Inc reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
- BVF Inc sold 2,560,916 Protagonist Therapeutics shares in Q4 2025, an estimated $170M.
- BVF Inc first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 31 quarters.
- BVF Inc's Protagonist Therapeutics position peaked at $177M in Q2 2025.
- 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.
Based on BVF Inc's 13F filing for Q4 2025, filed 17 Feb 2026.